Introduction
Poliomyelitis is an infectious disease caused by poliovirus, a positive-sense RNA enterovirus in the family Picornaviridae. Most infections produce no symptoms, but a small proportion invade the nervous system and can cause irreversible flaccid paralysis or death. The original essay correctly explains fecal–oral transmission, viral replication, the inactivated and oral vaccines, and the history of Salk and Sabin. It is outdated in listing India and Nigeria as endemic, understates the difference between wild and vaccine-derived poliovirus, and does not describe the present eradication endgame. Wild poliovirus type 1 remains endemic in Afghanistan and Pakistan. As of 15 July 2026, the Global Polio Eradication Initiative reported eleven wild-poliovirus cases in Afghanistan and three in Pakistan during 2026, along with positive environmental samples. Circulating vaccine-derived polioviruses continue to cause outbreaks in several countries when population immunity is low. The central challenge is no longer invention of an effective vaccine. It is reaching every child repeatedly, maintaining surveillance, managing conflict and misinformation, and eventually stopping all forms of poliovirus transmission.
Meaning of the Name
The word poliomyelitis comes from Greek roots referring to gray matter and spinal cord inflammation. The name reflects the virus’s preference for motor neurons in the anterior horn of the spinal cord when nervous-system invasion occurs. “Polio” is the common abbreviation. Infection should be distinguished from paralytic disease: millions of infections can circulate without obvious paralysis because most infected people are asymptomatic. This silent transmission is one reason eradication requires population surveillance rather than waiting for clinical cases.
The Virus
Poliovirus has a single-stranded positive-sense RNA genome enclosed in a protein capsid and lacks a lipid envelope. Its non-enveloped structure helps it survive in the gastrointestinal environment. Three wild serotypes historically circulated. Wild poliovirus types 2 and 3 have been certified eradicated, leaving wild type 1. Immunity is type-specific, which means protection against one serotype does not automatically guarantee protection against another. Vaccine strategies have changed as the serotypes and outbreak risks changed.
Ancient Evidence and Early Description
Art from ancient Egypt appears to show people with limb deformities consistent with paralytic polio, although retrospective diagnosis from images cannot be certain. In 1789, physician Michael Underwood described a disorder involving weakness of the lower limbs in children. During the nineteenth century, clinicians increasingly recognized poliomyelitis as a distinct disease. Large epidemics became particularly visible in Europe and North America during the late nineteenth and early twentieth centuries, when improved sanitation paradoxically delayed first exposure beyond infancy and reduced the protection previously supplied by maternal antibodies during early infection.
Epidemics and Public Fear
Polio epidemics closed swimming pools, disrupted travel, and created fear because healthy children could develop paralysis rapidly. Adults were also affected, including U.S. President Franklin D. Roosevelt, whose paralysis helped make rehabilitation and research publicly visible. Iron lungs supported people whose respiratory muscles failed. The disease became a symbol of modern epidemic vulnerability: improved urban systems had reduced many infections, yet polio remained unpredictable. Public fundraising, including the March of Dimes, supported scientific research and patient care.
Transmission
Poliovirus spreads mainly through the fecal–oral route, especially where sanitation, water, and hand hygiene are inadequate. It can also spread through oral–oral contact. An infected person can shed virus in stool for weeks, including when no symptoms occur. Crowding, population movement, low vaccination coverage, and weak sanitation facilitate circulation. The virus infects only humans, and no long-term nonhuman reservoir is known, making eradication biologically possible. Human behavior and health-system access determine whether that possibility is achieved.
Entry and Replication
After entering through the mouth, poliovirus replicates in the throat and gastrointestinal tract, including lymphoid tissue. It can enter the bloodstream, producing viremia. In most people, the immune system prevents further spread. In a small proportion, the virus reaches the central nervous system, possibly through the bloodstream or peripheral nerves, and destroys motor neurons. The severity depends on the location and number of neurons affected. Damage to motor neurons can cause weakness that persists after the acute infection has ended.
Asymptomatic and Minor Illness
Most infections are asymptomatic. Some people develop a minor illness with fever, fatigue, headache, sore throat, nausea, or gastrointestinal symptoms. These symptoms are not specific to polio. Because asymptomatic people can transmit virus, absence of paralysis does not mean absence of an outbreak. Vaccination campaigns must protect the whole community rather than only contacts of visibly ill patients.
Nonparalytic Polio
A smaller group develops nonparalytic meningitis with neck or back stiffness, headache, fever, muscle pain, and sensitivity. Recovery usually occurs without permanent paralysis. Clinical distinction from other viral meningitis requires laboratory testing. The original essay’s division into only paralytic and nonparalytic illness is useful but should be supplemented by the large asymptomatic group.
Paralytic Polio
Paralytic disease is rare relative to infection but can be devastating. It usually causes acute flaccid weakness with reduced muscle tone and reflexes, often asymmetrically. Sensation is generally preserved. Spinal polio affects limb and trunk muscles. Bulbar polio affects brainstem functions such as swallowing, speech, and breathing. Bulbospinal disease combines features. Respiratory involvement can be fatal without support. Recovery varies because surviving neurons can form new connections, but severe neuron loss causes lasting disability.
Post-Polio Syndrome
Decades after apparent recovery, some survivors develop new weakness, fatigue, pain, or reduced endurance. This is called post-polio syndrome. It is not a reactivation of contagious virus. One explanation is that motor neurons that compensated for earlier damage become less able to maintain enlarged networks over time. Management may include energy conservation, tailored exercise, respiratory assessment, mobility support, pain care, and avoidance of overuse. Polio eradication does not end society’s responsibility to survivors.
Diagnosis
Suspected acute flaccid paralysis requires urgent public-health investigation. Stool specimens collected promptly are central because poliovirus can be isolated or detected genetically. Throat and other samples may also contribute, while cerebrospinal fluid generally shows inflammation without reliably identifying the virus. Laboratories sequence detected virus to determine whether it is wild, vaccine-derived, or related to another isolate. One clinical case may indicate far wider silent transmission, so surveillance extends to contacts and communities.
Environmental Surveillance
Sewage sampling can detect poliovirus excreted by infected people before paralysis appears. Environmental surveillance is especially valuable in densely populated areas and where clinical reporting is incomplete. A positive sample does not necessarily mean a paralytic case has occurred, but it provides evidence of circulation or importation. The July 2026 country updates for Afghanistan and Pakistan included multiple wild-poliovirus-positive environmental samples, demonstrating why eradication cannot be judged by case counts alone.
The Salk Vaccine
Jonas Salk developed the inactivated polio vaccine, first widely introduced in 1955. IPV contains killed virus and is injected. It produces strong protection against paralytic disease and cannot cause vaccine-associated poliomyelitis because the virus is not live. It induces less intestinal immunity than oral vaccine, so a vaccinated person may in some circumstances still acquire and shed virus without becoming paralyzed. IPV is therefore crucial for individual protection and the eradication endgame, but its effect on transmission differs from OPV.
The Sabin Vaccine
Albert Sabin developed oral polio vaccines using weakened live viruses, deployed widely in the early 1960s. OPV is inexpensive, easy to administer, and produces strong intestinal immunity that helps stop person-to-person transmission. The attenuated virus can spread briefly to close contacts and improve community immunity. In very rare cases, it can cause vaccine-associated paralytic polio. More importantly for eradication, attenuated virus can circulate for an extended period in under-immunized communities and genetically change into circulating vaccine-derived poliovirus capable of causing paralysis.
Vaccine-Derived Poliovirus
Vaccine-derived poliovirus is often misunderstood as evidence that vaccination is more dangerous than wild polio. The outbreak risk occurs when weakened oral-vaccine virus circulates for a long time among too many unvaccinated people. High immunity stops that circulation. The solution is not to abandon vaccination during an outbreak but to raise coverage rapidly with the appropriate vaccine. Newer oral vaccine type 2 was designed to be more genetically stable than the older type 2 vaccine, though surveillance and high coverage remain necessary.
Routine Immunization
Vaccination schedules vary by country according to epidemiology and health policy. The United States uses IPV in childhood. Countries at risk may use combinations of IPV and oral vaccine through routine services and supplemental campaigns. The original four-dose U.S. schedule is one national example rather than a universal plan. Families should follow current local recommendations. Missed doses generally require completion of the series rather than restarting, subject to clinical guidance.
The Global Polio Eradication Initiative
The World Health Assembly launched the global eradication effort in 1988, when wild polio paralyzed hundreds of thousands of children annually across many countries. The initiative brings together national governments, WHO, Rotary International, CDC, UNICEF, the Gates Foundation, Gavi, communities, and other partners. Wild cases have fallen by more than 99 percent, and two wild serotypes have been eradicated. This achievement demonstrates the power of vaccination and surveillance while showing that the final chains of transmission are the hardest to interrupt.
India and Nigeria
The original essay lists India and Nigeria as endemic. India’s last wild-poliovirus case occurred in 2011, and the WHO South-East Asia Region was certified polio-free in 2014. The WHO African Region was certified free of indigenous wild poliovirus in 2020 after Nigeria interrupted transmission. Countries in these regions can still detect imported or vaccine-derived viruses, so certification does not permit complacency. “Polio-free” means a defined form of transmission has been interrupted under surveillance standards, not that every future risk is impossible.
Afghanistan in 2026
As of 15 July 2026, the Global Polio Eradication Initiative reported eleven wild poliovirus type 1 cases in Afghanistan for the year, including four reported that week with paralysis onset in May and June. Twelve positive environmental samples from several provinces were also reported. Access constraints, population movement, conflict, service disruption, and missed communities complicate vaccination. National and local workers continue campaigns under difficult and sometimes dangerous conditions. Eradication depends on sustained access and trust, not only vaccine supply.
Pakistan in 2026
Pakistan had reported three wild-poliovirus cases in 2026 as of 15 July, with the most recent paralysis onset on 7 April, plus continuing positive environmental detection. The country has made major progress but faces persistent transmission corridors, mobile populations, urban sanitation challenges, campaign fatigue, misinformation, and security risks to health workers. Pakistan’s experience shows that a low case count can coexist with environmental evidence and that interruption must be maintained across provinces and borders.
Conflict and Humanitarian Emergencies
The Syrian outbreak discussed in the original essay illustrates how war can reverse progress. Conflict destroys routine immunization, sanitation, laboratories, records, and trusted local services while displacing populations across borders. Similar risks arise in other emergencies. Polio programs need negotiation for access, mobile and cross-border vaccination, integration with nutrition and other care, and protection of health personnel. Emergency campaigns cannot substitute indefinitely for functioning routine health systems.
Misinformation and Trust
Rumors about fertility, religion, foreign surveillance, or vaccine safety can reduce acceptance. Distrust may also reflect real experiences of political neglect, coercion, poor services, or disrespect. Communication should involve local clinicians, religious leaders, women, survivors, and community organizations rather than rely only on national advertising. Families are more likely to trust a program that provides reliable broader healthcare and responds honestly to questions. Compulsory or punitive approaches can increase resistance and hide missed children.
Campaign Quality
High reported coverage can conceal children missed repeatedly because they are absent, mobile, unregistered, inaccessible, or intentionally excluded from records. Campaign quality requires mapping households, supervising teams, tracking refusals and absence, verifying vaccination independently, and returning to missed communities. Frontline workers need training, pay, security, and respectful working conditions. Eradication is achieved by reaching the last child, not by meeting a national average.
Cross-Border Coordination
Afghanistan and Pakistan share population movement and virus transmission. Campaign schedules, surveillance, vaccination points, and data therefore need coordination. Borders do not stop a virus, and labeling one country as the source can damage cooperation. Migrants, refugees, nomadic groups, and seasonal workers should receive vaccination without discrimination or fear that health information will be used against them.
Laboratory Containment
As poliovirus disappears from communities, laboratories and vaccine facilities holding infectious materials become a potential source of reintroduction. Countries must identify facilities, destroy unnecessary material, and contain essential stocks under strict safeguards. An accidental release after eradication could encounter populations with declining intestinal immunity. Containment is therefore part of the endgame rather than a technical issue separate from vaccination.
Transition From Oral Vaccine
Complete eradication ultimately requires stopping routine use of live oral vaccine after all relevant transmission has ended, because continued use carries a small risk of vaccine-derived circulation. The transition must be coordinated globally and supported by adequate IPV, surveillance, outbreak stockpiles, and containment. Stopping too early risks uncontrolled transmission; stopping too late continues seeding attenuated virus. The decision is a global collective-action problem in which every country’s preparedness matters.
Health-System Legacy
Polio programs have built laboratories, surveillance networks, cold chains, emergency operations centers, and trained community workers. These assets have supported responses to measles, Ebola, COVID-19, and other health threats. Transition planning should preserve useful capacity when polio funding declines. Workers whose knowledge made eradication possible should not be discarded abruptly. A successful legacy strengthens immunization and outbreak detection rather than leaving a vertical program that disappears after certification.
Care and Disability Rights
Prevention receives most attention, but survivors need rehabilitation, mobility devices, education, accessible infrastructure, respiratory support, and protection from discrimination. Charity narratives can reduce survivors to symbols of tragedy. Disability rights emphasize autonomy, participation, and removal of barriers. Eradication should be celebrated alongside investment in people living with the disease’s long-term effects.
What Eradication Requires
The remaining tasks are technically clear but operationally difficult: interrupt wild type 1 transmission in Afghanistan and Pakistan; stop circulating vaccine-derived outbreaks; maintain sensitive acute-flaccid-paralysis and environmental surveillance; achieve high routine immunization; protect workers; contain laboratory stocks; and coordinate eventual withdrawal of oral vaccine. Political commitment must continue even when cases are few, because the cost of resurgence would be global.
Conclusion
Poliovirus is an ancient human pathogen that usually spreads silently through the gastrointestinal tract but can invade motor neurons and cause permanent paralysis. IPV provides safe protection against paralytic disease, while OPV has been indispensable for stopping transmission but can generate vaccine-derived outbreaks when immunity is low. Global vaccination has eradicated wild types 2 and 3 and eliminated indigenous wild virus from most regions. The final wild type 1 transmission remains in Afghanistan and Pakistan, where July 2026 data show fourteen reported cases between them and continuing environmental detection. The history of polio is therefore both a scientific success and a warning. Vaccines work, but they must reach every community through trusted, secure, and accountable health systems. Eradication will be complete only when wild and vaccine-derived transmission have stopped, surveillance remains capable of detecting reintroduction, and survivors receive the support and rights they deserve.
References
Global Polio Eradication Initiative. (2026, July 15). Polio This Week.
World Health Organization. (2025). Poliomyelitis Fact Sheet.
Centers for Disease Control and Prevention. (2025). Polio Vaccination.
Mehndiratta, M. M., Mehndiratta, P., & Pande, R. (2014). Poliomyelitis: historical facts, epidemiology, and current challenges in eradication. The Neurohospitalist, 4(4), 223–229.
Nomoto, A. (2007). Molecular aspects of poliovirus pathogenesis. Proceedings of the Japan Academy, Series B, 83(8), 266–275.
Cite This Work
To export a reference to this article please select a referencing stye below:
Academic Master Education Team is a group of academic editors and subject specialists responsible for producing structured, research-backed essays across multiple disciplines. Each article is developed following Academic Master’s Editorial Policy and supported by credible academic references. The team ensures clarity, citation accuracy, and adherence to ethical academic writing standards
Content reviewed under Academic Master Editorial Policy.
